{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:37:35Z","timestamp":1792841855839,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FAPESP","award":["2025\/02119-2"],"award-info":[{"award-number":["2025\/02119-2"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"FAPESP","award":["2018\/13877-1"],"award-info":[{"award-number":["2018\/13877-1"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"FAPESP","award":["2019\/21910-1"],"award-info":[{"award-number":["2019\/21910-1"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CNPq","award":["142029\/2020-3;307928\/2023-3"],"award-info":[{"award-number":["142029\/2020-3;307928\/2023-3"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CNPq","award":["306294\/2019-2"],"award-info":[{"award-number":["306294\/2019-2"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CNPq","award":["312514\/2019-0"],"award-info":[{"award-number":["312514\/2019-0"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CAPES","award":["001"],"award-info":[{"award-number":["001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Concerns regarding local and systemic adverse effects associated with long-term use of corticosteroids has motivated the study of new therapeutic approaches for psoriasis treatment. This study evaluated the efficacy of a novel nanoformulation loaded with a hydrogen sulfide (H\u2082S)-releasing dexamethasone derivative (Dexa-TBZ) in an experimental psoriasis model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Psoriasis was induced with topical imiquimod, and mice were treated for 4\u00a0days with dexamethasone- (Dexa, control) or Dexa-TBZ-loaded nanoformulations. Erythema and scaling (assessed by a modified Psoriasis Area Severity Index), myeloperoxidase (MPO) activity, and spleen size were assessed for efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Daily topical treatment with either Dexa or Dexa-TBZ reduced scaling and erythema, with the last most likely related to decreased inflammation, as suggested by a marked reduction in MPO activity and neutrophil infiltration. Both treatments also reduced epidermal thickening, indicating comparable local therapeutic effects. However, Dexa caused a greater reduction in circulating leukocytes and spleen size, suggesting higher systemic exposure despite topical administration. In contrast, Dexa-TBZ showed limited systemic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although Dexa-TBZ did not demonstrate superior local efficacy, its lower systemic impact suggests an improved safety and tolerability profile, which may be advantageous for the long-term topical treatment of chronic conditions such as psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04228-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T18:31:17Z","timestamp":1792780277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of a Nanoformulated Hydrogen Sulfide-releasing Dexamethasone for Topical Treatment of Psoriasis"],"prefix":"10.1007","author":[{"given":"Daniel A. G.","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson R. A.","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Nicolas","family":"Muscara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Corvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Sparaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Santagada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caliendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frecentese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia Katia Pereira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7814-9647","authenticated-orcid":false,"given":"Luciana B.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"1","key":"4228_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, Huang Y-H, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"4228_CR2","first-page":"Cd011535","volume":"8","author":"E Sbidian","year":"2025","unstructured":"Sbidian E, Chaimani A, Guelimi R, Tai CC, Beytout Q, Choudhary C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2025;8(8):Cd011535.","journal-title":"Cochrane Database Syst Rev"},{"key":"4228_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00349-1","author":"L Eder","year":"2026","unstructured":"Eder L, Perez-Chada L, Liao W, Merola JF. Psoriasis. Lancet. 2026. https:\/\/doi.org\/10.1016\/S0140-6736(26)00349-1.","journal-title":"Lancet"},{"issue":"6","key":"4228_CR4","first-page":"15","volume":"19","author":"J Burshtein","year":"2026","unstructured":"Burshtein J, Zakria D, Bhutani T, Bunick CG, Costner M, DiRuggiero D, et al. Topical Prescription Therapy for Psoriasis: An Expert Position Paper on Limitations of Published Guidelines and Treatment Selection With Updated Recommendations. J Clin Aesthet Dermatol. 2026;19(6):15\u201321.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"4228_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.det.2024.02.010","volume":"42","author":"KC Aoki","year":"2024","unstructured":"Aoki KC, Wong S, Duong JQ, Feldman SR. Adherence to psoriasis therapies. Dermatol Clin. 2024;42(3):495\u2013506.","journal-title":"Dermatol Clin"},{"key":"4228_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1468-3083.2012.04523.x","volume":"26","author":"E Castela","year":"2012","unstructured":"Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, et al. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol. 2012;26:47\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4228_CR7","doi-asserted-by":"publisher","first-page":"106925","DOI":"10.1016\/j.ejps.2024.106925","volume":"203","author":"DAG Miranda","year":"2024","unstructured":"Miranda DAG, Cerqueira ARA, Muscar\u00e1 MN, Severino B, Caliendo G, Corvino A, et al. Development and evaluation of nanostructured systems for cutaneous delivery of H2S-releasing corticosteroids for skin inflammatory diseases. Eur J Pharm Sci. 2024;203:106925.","journal-title":"Eur J Pharm Sci"},{"key":"4228_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jare.2021.05.008","volume":"35","author":"A Corvino","year":"2022","unstructured":"Corvino A, Citi V, Fiorino F, Frecentese F, Magli E, Perissutti E, et al. H2S donating corticosteroids: design, synthesis and biological evaluation in a murine model of asthma. J Adv Res. 2022;35:267\u201377.","journal-title":"J Adv Res"},{"issue":"1","key":"4228_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/2045-9912-3-24","volume":"3","author":"E Ekundi-Valentim","year":"2013","unstructured":"Ekundi-Valentim E, Mesquita FP, Santos KT, de Paula MA, Florenzano J, Zanoni CI, et al. A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Med Gas Res. 2013;3(1):24.","journal-title":"Med Gas Res"},{"key":"4228_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.phrs.2016.11.006","volume":"115","author":"L Rodrigues","year":"2017","unstructured":"Rodrigues L, Ekundi-Valentim E, Florenzano J, Cerqueira AR, Soares AG, Schmidt TP, et al. Protective effects of exogenous and endogenous hydrogen sulfide in mast cell-mediated pruritus and cutaneous acute inflammation in mice. Pharmacol Res. 2017;115:255\u201366.","journal-title":"Pharmacol Res"},{"key":"4228_CR11","doi-asserted-by":"crossref","unstructured":"Coavoy-S\u00e1nchez SA, Cerqueira ARA, Teixeira SA, Santagada V, Andreozzi G, Corvino A, et al. Beneficial effects of two hydrogen sulfide (H(2)S)-releasing derivatives of dexamethasone with antioxidant activity on atopic dermatitis in mice. Pharmaceutics. 2023;15(7):1907.","DOI":"10.3390\/pharmaceutics15071907"},{"issue":"4","key":"4228_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1620\/tjem.228.325","volume":"228","author":"AK Alshorafa","year":"2012","unstructured":"Alshorafa AK, Guo Q, Zeng F, Chen M, Tan G, Tang Z, et al. Psoriasis is associated with low serum levels of hydrogen sulfide, a potential anti-inflammatory molecule. Tohoku J Exp Med. 2012;228(4):325\u201332.","journal-title":"Tohoku J Exp Med"},{"key":"4228_CR13","doi-asserted-by":"publisher","first-page":"128901","DOI":"10.1016\/j.colsurfa.2022.128901","volume":"646","author":"G Mojeiko","year":"2022","unstructured":"Mojeiko G, Apolin\u00e1rio AC, Salata GC, Chorilli M, Lopes LB. Optimization of nanoemulsified systems containing lamellar phases for co-delivery of celecoxib and endoxifen to the skin aiming for breast cancer chemoprevention and treatment. Colloids Surf A Physicochem Eng Asp. 2022;646:128901.","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"issue":"9","key":"4228_CR14","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1021\/acs.molpharmaceut.1c00319","volume":"18","author":"GC Salata","year":"2021","unstructured":"Salata GC, Malag\u00f3 ID, Carvalho Dartora VFM, Mar\u00e7al Pessoa AF, Fantini MCA, Costa SKP, et al. Microemulsion for prolonged release of fenretinide in the mammary tissue and prevention of breast cancer development. Mol Pharm. 2021;18(9):3401\u201317.","journal-title":"Mol Pharm"},{"key":"4228_CR15","doi-asserted-by":"publisher","first-page":"106635","DOI":"10.1016\/j.ejps.2023.106635","volume":"192","author":"RDA Miguel","year":"2024","unstructured":"Miguel RDA, Hirata AS, Salata GC, Apolin\u00e1rio AC, Barroso VM, Ishida K, et al. Topical delivery of seriniquinone for treatment of skin cancer and fungal infections is enabled by a liquid crystalline lamellar phase. Eur J Pharm Sci. 2024;192:106635.","journal-title":"Eur J Pharm Sci"},{"key":"4228_CR16","doi-asserted-by":"publisher","first-page":"107397","DOI":"10.1016\/j.jddst.2025.107397","volume":"113","author":"JR Nunes","year":"2025","unstructured":"Nunes JR, Martins TS, Lopes LB. Nanoemulsions for topical-transdermal administration of a retinoid: understanding the effects of oil phase and terpene concentration on nanoemulsion characteristics, irritation potential, skin penetration and cytotoxicity. J Drug Deliv Sci Technol. 2025;113:107397.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4228_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24699","author":"E Abd","year":"2015","unstructured":"Abd E, Namjoshi S, Mohammed YH, Roberts MS, Grice JE. Synergistic skin penetration enhancer and nanoemulsion formulations promote the human epidermal permeation of caffeine and naproxen. J Pharm Sci. 2015. https:\/\/doi.org\/10.1002\/jps.24699.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4228_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijpharm.2009.07.007","volume":"381","author":"S Savic","year":"2009","unstructured":"Savic S, Weber C, Savic MM, Muller-Goymann C. Natural surfactant-based topical vehicles for two model drugs: Influence of different lipophilic excipients on in vitro\/in vivo skin performance. Int J Pharm. 2009;381(2):220\u201330.","journal-title":"Int J Pharm"},{"issue":"Pt A","key":"4228_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ijbiomac.2020.09.167","volume":"165","author":"DV Giacone","year":"2020","unstructured":"Giacone DV, Dartora V, de Matos JKR, Passos JS, Miranda DAG, de Oliveira EA, et al. Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models. Int J Biol Macromol. 2020;165(Pt A):1055\u201365.","journal-title":"Int J Biol Macromol"},{"key":"4228_CR20","doi-asserted-by":"crossref","unstructured":"Costa ABC, Dar\u00e9 RG, Lopes LB. Vegetable Butter-Based Nanocarriers: Do Nanoparticulation and Quercetin Loading Modulate In vitro Cellular Effects Involved in Wound Healing? AAPS PharmSciTech. 2026;27(5).","DOI":"10.1208\/s12249-026-03490-8"},{"issue":"1-2","key":"4228_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpharm.2008.11.014","volume":"370","author":"S Hoeller","year":"2009","unstructured":"Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: a comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm. 2009;370(1\u20132):181\u20136.","journal-title":"Int J Pharm"},{"key":"4228_CR22","doi-asserted-by":"crossref","unstructured":"Costa-Fernandez S, Mattos JKR, Scheunemann GS, Salata GC, Chorilli M, Watanabe IS, et al. Nanostructured lipid carriers containing chitosan or sodium alginate for co-encapsulation of antioxidants and an antimicrobial agent for potential application in wound healing. Int J Biologic Macromol. 2021;183:668-680.","DOI":"10.1016\/j.ijbiomac.2021.04.168"},{"key":"4228_CR23","doi-asserted-by":"crossref","unstructured":"Santos RA, Rae M, V FMCD, Matos JKR, Camarini R, Lopes LB. Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: development and biological evaluation. Int J Pharm. 2020:119474.","DOI":"10.1016\/j.ijpharm.2020.119474"},{"issue":"3","key":"4228_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s11095-012-0908-0","volume":"30","author":"JM Hosmer","year":"2013","unstructured":"Hosmer JM, Steiner AA, Lopes LB. Lamellar liquid crystalline phases for cutaneous delivery of Paclitaxel: impact of the monoglyceride. Pharm Res. 2013;30(3):694\u2013706.","journal-title":"Pharm Res"},{"issue":"9","key":"4228_CR25","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol. 2009;182(9):5836\u201345.","journal-title":"J Immunol"},{"key":"4228_CR26","unstructured":"Schmidt T. Avalia\u00e7\u00e3o farmacol\u00f3gica de uma nanodispers\u00e3o contendo GYY4137 (doador de libera\u00e7\u00e3o lenta de H2S) na psor\u00edase experimental. [disserta\u00e7\u00e3o]. S\u00e3o Paulo: Universidade de S\u00e3o Paulo, Instituto de Ci\u00eancias Biom\u00e9dicas; 2016 [citado 2026-10-15]."},{"issue":"7130","key":"4228_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866\u201373.","journal-title":"Nature"},{"key":"4228_CR28","doi-asserted-by":"crossref","unstructured":"Jabeen M, Boisgard AS, Danoy A, El Kholti N, Salvi JP, Boulieu R, et al. Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics. 2020;12(9):789.","DOI":"10.3390\/pharmaceutics12090789"},{"issue":"9","key":"4228_CR29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1365-4362.1988.tb02422.x","volume":"27","author":"CH Liu","year":"1988","unstructured":"Liu CH, Ji MR, Fang X, Wang HY, Lin GF. Peripheral leukocytes in psoriasis. Int J Dermatol. 1988;27(9):638\u201341.","journal-title":"Int J Dermatol"},{"issue":"8","key":"4228_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/labinvest.2011.76","volume":"91","author":"P Mirandola","year":"2011","unstructured":"Mirandola P, Gobbi G, Micheloni C, Vaccarezza M, Di Marcantonio D, Ruscitti F, et al. Hydrogen sulfide inhibits IL-8 expression in human keratinocytes via MAP kinase signaling. Lab Invest. 2011;91(8):1188\u201394.","journal-title":"Lab Invest"},{"issue":"Pt A","key":"4228_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.phrs.2016.09.030","volume":"113","author":"SA Coavoy-Sanchez","year":"2016","unstructured":"Coavoy-Sanchez SA, Rodrigues L, Teixeira SA, Soares AG, Torregrossa R, Wood ME, et al. Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice. Pharmacol Res. 2016;113(Pt A):686\u201394.","journal-title":"Pharmacol Res"},{"key":"4228_CR32","first-page":"e68111","volume":"220","author":"M Que","year":"2025","unstructured":"Que M, Wei Y, Wu S, Liang X, Zhang K, Wu G. Establishment of Psoriasis Mouse Model by Imiquimod. JoVE. 2025;220:e68111.","journal-title":"JoVE"},{"issue":"2","key":"4228_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/bjd.13236","volume":"172","author":"H Vinter","year":"2015","unstructured":"Vinter H, Iversen L, Steiniche T, Kragballe K, Johansen C. Aldara\u00ae-induced skin inflammation: studies of patients with psoriasis. Br J Dermatol. 2015;172(2):345\u201353.","journal-title":"Br J Dermatol"},{"issue":"s2","key":"4228_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","volume":"24","author":"E Puzenat","year":"2010","unstructured":"Puzenat E, Bronsard V, Prey S, Gourraud P-A, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(s2):10\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4228_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"DM Ashcroft","year":"1999","unstructured":"Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185\u201391.","journal-title":"Br J Dermatol"},{"key":"4228_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","volume":"7","author":"GK Perera","year":"2012","unstructured":"Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385\u2013422.","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"4228_CR37","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1002\/eji.201343801","volume":"43","author":"B Flutter","year":"2013","unstructured":"Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013;43(12):3138\u201346.","journal-title":"Eur J Immunol"},{"key":"4228_CR38","doi-asserted-by":"crossref","unstructured":"Park SH, Lee JH, Yoon KN, Yang G, Kim J, Lee JY, et al. Anti-psoriatic effects of J2H-1802, a mycophenolate mofetil and 5-aminosalicylic acid hybrid, in an imiquimod-induced psoriasis-like mouse model. Pharmaceutics. 2026;18(3):380.","DOI":"10.3390\/pharmaceutics18030380"},{"issue":"5","key":"4228_CR39","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1208\/s12249-016-0643-7","volume":"18","author":"VF Carvalho","year":"2017","unstructured":"Carvalho VF, de Lemos DP, Vieira CS, Migotto A, Lopes LB. Potential of non-aqueous microemulsions to improve the delivery of lipophilic drugs to the skin. AAPS PharmSciTech. 2017;18(5):1739\u201349.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"4228_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0928-0987(01)00167-1","volume":"14","author":"BW Barry","year":"2001","unstructured":"Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101\u201314.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"4228_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.4155\/tde.15.61","volume":"6","author":"LB Lopes","year":"2015","unstructured":"Lopes LB, Garcia MT, Bentley MV. Chemical penetration enhancers. Ther Deliv. 2015;6(9):1053\u201361.","journal-title":"Ther Deliv"},{"key":"4228_CR42","doi-asserted-by":"publisher","first-page":"126234","DOI":"10.1016\/j.ijpharm.2025.126234","volume":"685","author":"J Guo","year":"2025","unstructured":"Guo J, Zhang L, Li Z, Zhang Y, Yang N, Tang H, et al. A transdermal drug delivery system based on estradiol liposomes enhances the alleviation of psoriatic skin inflammation. Int J Pharm. 2025;685:126234.","journal-title":"Int J Pharm"},{"issue":"30","key":"4228_CR43","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1080\/17435889.2024.2405455","volume":"19","author":"S Thatikonda","year":"2024","unstructured":"Thatikonda S, Rasoju SP, Pooladanda V, Chilvery S, Khemchandani R, Samanthula G, et al. Niosomal gel improves dermal delivery of nimbolide: a promising approach for treatment of psoriasis. Nanomedicine. 2024;19(30):2521\u201336.","journal-title":"Nanomedicine"},{"issue":"4","key":"4228_CR44","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1053\/j.gastro.2005.07.060","volume":"129","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi S, et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology. 2005;129(4):1210\u201324.","journal-title":"Gastroenterology"},{"key":"4228_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4939-2895-8_5","volume":"872","author":"T Kuo","year":"2015","unstructured":"Kuo T, McQueen A, Chen TC, Wang JC. Regulation of glucose homeostasis by glucocorticoids. Adv Exp Med Biol. 2015;872:99\u2013126.","journal-title":"Adv Exp Med Biol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04228-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:08Z","timestamp":1792839728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04228-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":45,"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04228-8","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nothing to declare.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}